Literature DB >> 2288831

Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.

B Marasini1, C Bassani.   

Abstract

1. The effect of ketanserin on digital blood flow and 5-hydroxytryptamine (5-HT)-induced platelet aggregation was studied in 18 patients with Raynaud's phenomenon. 2. Measurements were made before and after a single dose of 20 mg ketanserin and again after 1 month of continuous treatment with 20 mg ketanserin three times a day. 3. Digital blood flow was assessed by changes in digital pulse volume; platelet aggregation by changes in light transmission after challenge with 10(-5) M 5-HT. 4. Ketanserin induced a rise in digital blood flow and blocked the platelet response to 5-HT; the two events were not correlated and were independent of subjective improvement. 5. These data do not support the suggestion that 5-HT2-receptor blockade is of major importance in the dilatory effect of ketanserin in Raynaud's phenomenon.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2288831      PMCID: PMC1368305          DOI: 10.1111/j.1365-2125.1990.tb05450.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?

Authors:  R M Brouwer; G J Wenting; W Visser; M A Schalekamp
Journal:  Vasa Suppl       Date:  1987

2.  Vascular physiology: the end of the quest?

Authors:  P M Vanhoutte
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

3.  Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.

Authors:  B Marasini; M L Biondi; E Bianchi; P Dell'Orto; A Agostoni
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  International study of ketanserin in Raynaud's phenomenon.

Authors:  J D Coffman; D L Clement; M A Creager; J A Dormandy; M M Janssens; R J McKendry; G D Murray; S L Nielsen
Journal:  Am J Med       Date:  1989-09       Impact factor: 4.965

5.  5HT3 receptor-mediated vasodilation in the human forearm.

Authors:  G J Blauw; P van Brummelen; P C Chang; P Vermeij; P A van Zwieten
Journal:  J Hypertens Suppl       Date:  1988-12

6.  Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.

Authors:  R Amstein; N Fetkovska; A Pletscher; F R Bühler
Journal:  J Hypertens       Date:  1989-04       Impact factor: 4.844

7.  Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.

Authors:  E Stranden; O K Roald; K Krohg
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-16

8.  Adrenergic and serotoninergic mechanisms in human hand arteries and veins studied by fluorescence histochemistry and in vitro pharmacology.

Authors:  B Arneklo-Nobin; C Owman
Journal:  Blood Vessels       Date:  1985

9.  Alpha-adrenergic and serotonergic mechanisms in the human digit.

Authors:  J D Coffman; R A Cohen
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

10.  Regional vascular effects of serotonin and ketanserin in young, healthy subjects.

Authors:  G J Blauw; P van Brummelen; P C Chang; P Vermeij; P A van Zwieten
Journal:  Hypertension       Date:  1988-03       Impact factor: 10.190

View more
  1 in total

Review 1.  Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.